Further, since we have identified EGFR, to be at least one of the binding partners to which SPINK1 signals in HCC, it may be worthwhile to explore on the application of EGFR inhibitor to possibly widen the therapeutic window for chemotherapy in the clinic. This evidence concerns the gene EGFR and hepatocellular carcinoma.